 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Cabozantinib and Nivolumab Effective in Most Non-Clear Cell Renal Cancers

J Clin Oncol: Cabozantinib and Nivolumab Effective in Most Non-Clear Cell Renal Cancers

 Last Update: 2022-04-23
 Source: Internet
 Author: User

Tags

cell fixation

influenzae treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Renal cell carcinoma (RCC) accounts for 90% of kidney cancer cases, of which approximately 70% are of the clear cell carcinoma (ccRCC) subtype
.

Other histological variants, collectively termed non-clear cell renal carcinoma (nccRCC), include genetically and histologically diverse tumors

This study was designed to evaluate the efficacy and safety of cabozantinib combined with nivolumab in the treatment of non-clear cell renal cancer
.

To evaluate the efficacy and safety of cabozantinib combined with nivolumab in the treatment of non-clear cell renal cancer

Recruited patients with advanced non-clear cell renal cancer who had not received immune checkpoint inhibitor therapy before and received 0-1 previous treatments and received cabozantinib 40 mg (1/day) + nivolumab 240 mg (1 /2 weeks) or 480 mg (1/4 weeks)
.

Cohort 1 included papillary, unclassified, or translocation-related renal cell carcinoma; cohort 2 included chromophobe renal cell carcinoma

immunity

Objective response rates for cohort 1 and cohort 2

A total of 47 patients were recruited with a median follow-up of 13.
1 months
.

In Cohort 1 (n=40), the objective response rate was 47.

PFS and OS in cohort 1 patients

Grade 3/4 treatment-related adverse reactions were reported in 32% of patients
.

Cabozantinib and nivolumab were discontinued due to toxicity in 13% and 17% of patients, respectively

Objective responses were achieved in 10 of 12 patients with NF2 or FH mutations

Cabozantinib in combination with nivolumab has shown promising efficacy in most non-clear cell renal cancers, especially in the subtype with papillary features .

Original source:

Chung-Han Lee, et al.

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.